Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Ann Surg. 2022 Jul 1;276(1):111-118. doi: 10.1097/SLA.0000000000004317. Epub 2020 Nov 16.
To evaluate perioperative and oncologic outcomes in our RAMIE cohort and compare outcomes with contemporary OE controls.
RAMIE has emerged as an alternative to traditional open or laparoscopic approaches. Described in all esophagectomy techniques, rapid adoption has been attributed to both enhanced visualization and technical dexterity.
We retrospectively reviewed patients who underwent RAMIE for malignancy. Patient characteristics, perioperative outcomes, and survival were evaluated. For perioperative and oncologic outcome comparison, contemporary OE controls were propensity-score matched from NSQIP and NCDB databases.
We identified 350 patients who underwent RAMIE between 2010 and 2019. Median body mass index was 27.4, 32% demonstrated a Charlson Comorbidity Index >4. Nodal disease was identified in 50% of patients and 74% received neoadjuvant chemoradiotherapy. Mean operative time and blood loss were 425 minutes and 232 mL, respectively. Anastomotic leak occurred in 16% of patients, 2% required reoperation. Median LOS was 9 days, and 30-day mortality was 3%. A median of 21 nodes were dissected with 96% achieving an R0 resection. Median survival was 67.4 months. 222 RAMIE were matched 1:1 to the NSQIP OE control. RAMIE demonstrated decreased LOS (9 vs 10 days, P = 0.010) and reoperative rates (2.3 vs 12.2%, P = 0.001), longer operative time (427 vs 311 minutes, P = 0.001), and increased rate of pulmonary embolism (5.4% vs 0.9%, P = 0.007) in comparison to NSQIP cohort. There was no difference in leak rate or mortality. Three hundred forty-three RAMIE were matched to OE cohort from NCDB with no difference in median overall survival (63 vs 53 months; P = 0.130).
In this largest reported institutional series, we demonstrate that RAMIE can be performed safely with excellent oncologic outcomes and decreased hospital stay when compared to the open approach.
评估我们的 RAMIE 队列的围手术期和肿瘤学结果,并将结果与当代 OE 对照进行比较。
RAMIE 已成为传统开放或腹腔镜方法的替代方法。在所有食管癌手术技术中均有描述,其快速采用归因于增强的可视化和技术灵活性。
我们回顾性分析了 2010 年至 2019 年间接受 RAMIE 治疗恶性肿瘤的患者。评估了患者特征、围手术期结果和生存率。为了进行围手术期和肿瘤学结果比较,从 NSQIP 和 NCDB 数据库中使用倾向评分匹配了当代 OE 对照。
我们确定了 2010 年至 2019 年间接受 RAMIE 治疗的 350 名患者。中位体质指数为 27.4,32%的患者 Charlson 合并症指数>4。50%的患者存在淋巴结疾病,74%的患者接受了新辅助放化疗。平均手术时间和出血量分别为 425 分钟和 232ml。吻合口漏发生在 16%的患者中,2%的患者需要再次手术。中位住院时间为 9 天,30 天死亡率为 3%。中位数切除 21 个淋巴结,96%达到 R0 切除。中位总生存期为 67.4 个月。222 例 RAMIE 与 NSQIP OE 对照进行了 1:1 匹配。与 NSQIP 队列相比,RAMIE 显示出较短的住院时间(9 天 vs 10 天,P = 0.010)和再手术率(2.3% vs 12.2%,P = 0.001)、较长的手术时间(427 分钟 vs 311 分钟,P = 0.001)和增加的肺栓塞发生率(5.4% vs 0.9%,P = 0.007)。两组在漏率或死亡率方面无差异。343 例 RAMIE 与 NCDB 的 OE 队列相匹配,中位总生存期无差异(63 个月 vs 53 个月;P = 0.130)。
在这项最大的机构报告系列中,我们证明与开放方法相比,RAMIE 可以安全进行,具有出色的肿瘤学结果并缩短住院时间。